What We Do
From researchers at academic medical centers and veterinary medical clinics to individual consumers, Mobile Biosensing Diagnostics (MBD) revolutionizes diagnosis at the point-of-care, not the lab. With an optical microfluidic biosensing platform, we speed disease detection at a lower cost. MBD is bringing personalized medicine to the masses.
The Product
- Offer instrumentation at no cost, then sell reagents and services
- PHASE 1: Research-use only test kits then direct-to-customer kits
- PHASE 2: Veterinary in vitro diagnostic kits and testing services
- PHASE 3: Human in vitro diagnostic test kits and testing services
Target Customer Pain Points
- Academic research labs and veterinary medicine need lower cost diagnostic solutions while preserving the sample
- Individuals crave answers, even anecdotal and non-diagnostic
- Hospitals and diagnostic labs performing biopsies need cheaper, safer alternatives with faster recovery and results
- Retail pharmacies need additional revenue streams
Differentiation
- Low cost, highly accurate, mobile point-of-care diagnostic platform
- Incorporates detection of genome, proteome, secretome targets with the same urine, blood, or lavage sample
- Quantifies protein activity, improves sensitivity, streamlines processing, and simplifies the user experience
Market Size
Global in vitro diagnostics market is estimated to reach $75.1 billion by 2020. The emerging liquid biopsy market is gaining traction as a $15 billion market during the same period.
Progress & Milestones
- Maintain patent and expand intellectual property portfolio
- Complete pilot to clinically validate hardware, software, and conclusions
- Established partnerships with established in vitro diagnostic companies
- Prepared for early stage product dev & testing at KSU Veterinary School
Advisors
- Alan Brasier, MD
- Stefan Bossmann, PhD
- Massoud Matamedi, PhD
- Chris Culbertson, PhD
Management Team
- Alexander Vo, PhD
- Chris Brandt, JD
- Ryan Westberry, MS, MBA
Download this document